Liver cancer trial with doxorubicin Transdrug suspended on safety
This article was originally published in Scrip
BioAlliance Pharmahas suspended its Phase II/III trial of doxorubicin Transdrug in inoperable liver cancer on the advice of the study's data safety monitoring board (DSMB) which found more frequent and severe pulmonary adverse events than expected.
You may also be interested in...
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.